{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-247446","form_type":"8-K","ticker":"BHC","cik":"0000885590","company_name":"Bausch Health Companies Inc.","filed_at":"2023-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.878052+00:00","generated_at":"2026-06-10T07:17:02.033992+00:00","sec_items":["1.01","2.01","9.01","2.03"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bausch + Lomb completes $2.5B XIIDRA acquisition from Novartis, funded with $1.9B debt","bullets":["Upfront $1.75B cash plus up to $750M milestone for XIIDRA and other ophthalmology assets from Novartis.","Funded by $1.4B 8.375% senior secured notes due 2028 and $500M term B loans.","Notes mature Oct 1, 2028; interest payable semi-annual; secured by first-priority liens.","Bausch + Lomb also acquired the sales force supporting XIIDRA.","Closing occurred September 29, 2023, consistent with prior announcements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-247446","json":"https://secwatch.observer/filing/0001193125-23-247446.json","markdown":"https://secwatch.observer/filing/0001193125-23-247446.md","text":"https://secwatch.observer/filing/0001193125-23-247446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885590/000119312523247446/0001193125-23-247446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885590/000119312523247446/d490226d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:17:02.033992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6d82fccbdbd86ad43b49f343a4e950fa1423e3d","claim":"Bausch Health Companies Inc. incurred term loan of $500,000,000 of new term loans with Bausch + Lomb Corporation at at a rate per annum equal to, at the borrower’s option, either (a) a base rate d maturing September 29, 2028.","evidence_excerpt":"On September 29, 2023, Bausch + Lomb entered into an amendment (the “First Incremental Amendment”) to the credit and guaranty agreement, dated as of May 10, 2022 (the “Credit Agreement,” and as amended by the First Incremental Amendment, the “Amended Credit Agreement”), by and among Bausch + Lomb, certain subsidiaries of Bausch + Lomb as subsidiary guarantors, the lenders party thereto, Citibank, N.A., in its capacity as collateral agent, Goldman Sachs Bank USA, in its capacity as term facility administrative agent, and JPMorgan Chase Bank, N.A., in its capacity as first incremental term facility administrative agent, pursuant to which Bausch + Lomb borrowed $500,000,000 of new term loans (the “First Incremental Term Loans”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/885590/000119312523247446/0001193125-23-247446-index.htm","confidence":0.99,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$500,000,000 of new term loans"},{"label":"Counterparty","value":"Bausch + Lomb Corporation"},{"label":"Rate","value":"at a rate per annum equal to, at the borrower’s option, either (a) a base rate d"},{"label":"Maturity","value":"September 29, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"fba9d4f441f73d64beab590bd583b461210e4d6a","claim":"Bausch Health Companies Inc. incurred senior notes of $1,400,000,000 aggregate principal amount with Bausch + Lomb Corporation at 8.375% maturing October 1, 2028.","evidence_excerpt":"On September 29, 2023, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc. (the “Company”), completed its previously announced offering of $1,400,000,000 aggregate principal amount of its 8.375% Senior Secured Notes due 2028 (the “Notes”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/885590/000119312523247446/0001193125-23-247446-index.htm","confidence":0.99,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$1,400,000,000 aggregate principal amount"},{"label":"Counterparty","value":"Bausch + Lomb Corporation"},{"label":"Rate","value":"8.375%"},{"label":"Maturity","value":"October 1, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"40b49273d598bfe01cda04fed1509dc7ff018db0","claim":"Bausch Health Companies Inc. completed an acquisition involving Novartis Pharma AG and Novartis Finance Corporation (closed 2023-09-29).","evidence_excerpt":"On September 29, 2023, Bausch + Lomb completed the Acquisition pursuant to the terms and conditions of the previously announced Stock and Asset Purchase Agreement","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/885590/000119312523247446/0001193125-23-247446-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Novartis Pharma AG and Novartis Finance Corporation"},{"label":"Closing","value":"2023-09-29"}],"fact_type":"ma_transaction"},{"claim_id":"7a1b2789b1f004667644a8ae3a0a671fab452671","claim":"Bausch Health Companies Inc. entered into First Incremental Amendment to Bausch + Lomb Credit Agreement with Citibank, N.A., Goldman Sachs Bank USA, JPMorgan Chase Bank, N.A. valued at $500,000,000 (effective 2023-09-29).","evidence_excerpt":"On September 29, 2023, Bausch + Lomb entered into an amendment (the “First Incremental Amendment”) to the credit and guaranty agreement, dated as of May 10, 2022 (the “Credit Agreement,” and as amended by the First Incremental Amendment, the “Amended Credit Agreement”), by and among Bausch + Lomb, certain subsidiaries of Bausch + Lomb as subsidiary guarantors, the lenders party thereto, Citibank, N.A., in its capacity as collateral agent, Goldman Sachs Bank USA, in its capacity as term facility administrative agent, and JPMorgan Chase Bank, N.A., in its capacity as first incremental term facility administrative agent, pursuant to which Bausch + Lomb borrowed $500,000,000 of new term loans (the “First Incremental Term Loans”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885590/000119312523247446/0001193125-23-247446-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Citibank, N.A., Goldman Sachs Bank USA, JPMorgan Chase Bank, N.A."},{"label":"Value","value":"$500,000,000"},{"label":"Effective","value":"2023-09-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}